Ex vivo assessment of vascular response to coronary stents by optical frequency domain imaging.

OBJECTIVES This study sought to examine the capability of optical frequency domain imaging (OFDI) to characterize various morphological and histological responses to stents implanted in human coronary arteries. BACKGROUND A precise assessment of vascular responses to stents may help stratify the risk of future adverse events in patients who have been treated with coronary stents. METHODS Fourteen human stented coronary segments with implant duration ≥ 1 month from 10 hearts acquired at autopsy were interrogated ex vivo by OFDI and intravascular ultrasound (IVUS). Comparison with histology was assessed in 134 pairs of images where the endpoints were to investigate: 1) accuracy of morphological measurements; 2) detection of uncovered struts; and 3) characterization of neointima. RESULTS Although both OFDI and IVUS provided a good correlation of neointimal area with histology, the correlation of minimum neointimal thickness was inferior in IVUS (R(2) = 0.39) as compared with OFDI (R(2) = 0.67). Similarly, IVUS showed a weak correlation of the ratio of uncovered to total stent struts per section (RUTSS) (R(2) = 0.24), whereas OFDI maintained superiority (R(2) = 0.66). In a more detailed analysis by OFDI, identification of individual uncovered struts demonstrated a sensitivity of 77.9% and specificity of 96.4%. Other important morphological features such as fibrin accumulation, excessive inflammation (hypersensitivity), and in-stent atherosclerosis were characterized by OFDI; however, the similarly dark appearance of these tissues did not allow for direct visual discrimination. The quantitative analysis of OFDI signal reflections from various in-stent tissues demonstrated distinct features of organized thrombus and accumulation of foamy macrophages. CONCLUSIONS The results of the present study reinforce the potential of OFDI to detect vascular responses that may be important for the understanding of long-term stent performance, and indicate the capability of this technology to serve as a diagnostic indicator of clinical success.

[1]  R. Virmani,et al.  Extracellular Matrix Changes in Stented Human Coronary Arteries , 2004, Circulation.

[2]  R. Virmani,et al.  Histopathologic analysis of in‐stent neointimal regression in a porcine coronary model , 2000, Coronary artery disease.

[3]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[4]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.

[5]  Fernando Alfonso,et al.  Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. , 2005, Journal of the American College of Cardiology.

[6]  Hiram G Bezerra,et al.  Strut Coverage and Vessel Wall Response to a New-Generation Paclitaxel-Eluting Stent With an Ultrathin Biodegradable Abluminal Polymer: Optical Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI) , 2010, Circulation. Cardiovascular interventions.

[7]  Very late thrombosis of sirolimus-eluting stent due to late malapposition: serial observations with optical coherence tomography. , 2008, Journal of cardiology.

[8]  R. Virmani,et al.  Small black holes in optical frequency domain imaging matches intravascular neoangiogenesis formation in histology. , 2010, European heart journal.

[9]  Peter Jüni,et al.  Correlation of Intravascular Ultrasound Findings With Histopathological Analysis of Thrombus Aspirates in Patients With Very Late Drug-Eluting Stent Thrombosis , 2009, Circulation.

[10]  Gregg W Stone,et al.  Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. , 2010, The New England journal of medicine.

[11]  Y. Jang,et al.  Mini-Focus Issue: Second-Generation DESEvaluation in 3 Months Duration of Neointimal Coverage After Zotarolimus-Eluting Stent Implantation by Optical Coherence Tomography: The ENDEAVOR OCT Trial , 2009 .

[12]  Gregg W Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.

[13]  E. Halpern,et al.  Characterization of Human Atherosclerosis by Optical Coherence Tomography , 2002, Circulation.

[14]  Eiji Toyota,et al.  Assessment of coronary arterial thrombus by optical coherence tomography. , 2006, The American journal of cardiology.

[15]  Giuseppe Biondi-Zoccai,et al.  Strut coverage and vessel wall response to zotarolimus-eluting and bare-metal stents implanted in patients with ST-segment elevation myocardial infarction: the OCTAMI (Optical Coherence Tomography in Acute Myocardial Infarction) Study. , 2010, JACC. Cardiovascular interventions.

[16]  H. Gold,et al.  Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. , 2002, Journal of the American College of Cardiology.

[17]  Paul G Yock,et al.  In vivo comparison between optical coherence tomography and intravascular ultrasound for detecting small degrees of in-stent neointima after stent implantation. , 2008, JACC. Cardiovascular interventions.

[18]  Eloisa Arbustini,et al.  Sources of error and interpretation of plaque morphology by optical coherence tomography. , 2006, The American journal of cardiology.

[19]  S. Yun,et al.  Removing the depth-degeneracy in optical frequency domain imaging with frequency shifting. , 2004, Optics express.

[20]  R. Virmani,et al.  Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. , 2011, Journal of the American College of Cardiology.

[21]  Matthew H Samore,et al.  Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. , 2006, Journal of the American College of Cardiology.

[22]  Ruslan Hlushchuk,et al.  Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy , 2010, European heart journal.

[23]  Aloke V. Finn,et al.  Delayed Arterial Healing and Increased Late Stent Thrombosis at Culprit Sites After Drug-Eluting Stent Placement for Acute Myocardial Infarction Patients: An Autopsy Study , 2008, Circulation.

[24]  David Levitz,et al.  Non-destructive label-free monitoring of collagen gel remodeling using optical coherence tomography. , 2010, Biomaterials.

[25]  David Levitz,et al.  Quantitative characterization of developing collagen gels using optical coherence tomography. , 2010, Journal of biomedical optics.

[26]  Yoshihiko Seino,et al.  Appearance of lipid-laden intima and neovascularization after implantation of bare-metal stents extended late-phase observation by intracoronary optical coherence tomography. , 2009, Journal of the American College of Cardiology.

[27]  Armando Tellez,et al.  Accuracy of optical coherence tomography in the evaluation of neointimal coverage after stent implantation. , 2010, JACC. Cardiovascular imaging.

[28]  Seung‐Jung Park,et al.  Intravascular ultrasound findings in patients with very late stent thrombosis after either drug-eluting or bare-metal stent implantation. , 2010, Journal of the American College of Cardiology.

[29]  K. Seung,et al.  Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound. , 2002, Journal of the American College of Cardiology.

[30]  K. Kodama,et al.  Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: an angioscopic study. , 2009, JACC. Cardiovascular imaging.

[31]  R. Virmani,et al.  Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization , 2007, Circulation.

[32]  Serial angiographic and endovascular documentation of peri-stent contrast stains after sirolimus-eluting stent implantation: Multiple cavity formations between entirely covered stent struts. , 2010, Journal of cardiology cases.

[33]  Giuseppe Musumeci,et al.  Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.

[34]  Michael Joner,et al.  Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications , 2007, Circulation.